AA
NVLN

Ancora Advisors’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Ancora Advisors’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,911
Closed -$15K – 1288
2018
Q3 		$15K Buy
+4,911
New +$17.4K ﹤0.01% 1131
2018
Q1 		– Sell
-23,137
Closed -$72K – 710
2017
Q4 		$72K Sell
23,137
-116,124
-83% -$558K ﹤0.01% 616
2017
Q3 		$979K Sell
139,261
-368,720
-73% -$2.95M 0.06% 327
2017
Q2 		$4.69M Buy
507,981
+2,070
+0.4% +$19.9K 0.3% 100
2017
Q1 		$5.43M Sell
505,911
-54,702
-10% -$559K 0.37% 76
2016
Q4 		$4.72M Buy
+560,613
New +$4.97M 0.34% 82

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ancora Advisors's NVLN Position: Q4 2018 in Review

Ancora Advisors sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 4,911 shares — an estimated $15K sold.

Ancora Advisors first reported a position in NVLN in Q4 2016 and held it in 6 quarters. The position peaked at $5.43M in Q1 2017. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

  • Ancora Advisors reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
  • Ancora Advisors sold 4,911 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $15K.
  • Ancora Advisors first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 6 quarters.
  • Ancora Advisors's Novelion Therapeutics Inc. Common Shares position peaked at $5.43M in Q1 2017.
  • 36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Ancora Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.